Drug Detail

Drug Name Nivolumab
Trade Name Opdivo
Synonyms MDX-1106|BMS-936558
Drug Descriptions

Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (NCI Drug Dictionary). Opdivo (nivolumab) is FDA approved for the treatment of metastatic melanoma, squamous NSCLC, metastatic small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR or MSI-H colorectal cancer as a single agent or in combination with Yervoy (ipilimumab) (FDA.gov).

DrugClasses Immune Checkpoint Inhibitor 99 PD-L1/PD-1 antibody 49

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
APX005M + NEO-PV-01 + Nivolumab + poly ICLC
BMS-986226 + Nivolumab
AdV-tk + Nivolumab
Cabozantinib + Ipilimumab + Nivolumab
Abemaciclib + Nivolumab
Ipilimumab + Nintedanib + Nivolumab
Ipilimumab + Mocetinostat + Nivolumab
Nivolumab + Trametinib
Fluorouracil + Irinotecan + Leucovorin + Nivolumab
MVA-MUC1-IL2 vaccine + Nivolumab
BMS-986258 + Nivolumab
Nivolumab + Urelumab
Nivolumab + rhIL-15
Ipilimumab + NEO-PV-01 + Nivolumab + poly ICLC
PROSTVAC-V/TRICOM + Nivolumab + Ipilimumab
Nivolumab + WT1 vaccine
CRS-207 + Ipilimumab + Nivolumab
EB-VST cells + Nivolumab
MLN1202 + Nivolumab
Ipilimumab + Nivolumab + VX15/2503
HPVSTs + Cyclophosphamide + Fludarabine phosphate + Nivolumab
Ipilimumab + Nivolumab + Panitumumab
Nivolumab + trifluridine/tipiracil hydrochloride
INCAGN01876 + Nivolumab
Nazartinib + Nivolumab
Nivolumab + Pazopanib
Nivolumab + Varlilumab
Dabrafenib + Nivolumab + Trametinib
Bevacizumab + Nivolumab
Nivolumab + X4P-001
Nimotuzumab + Nivolumab
Cyclophosphamide + GVAX pancreatic cancer vaccine + Nivolumab
Ipilimumab + Nivolumab + rhIL-15
Nivolumab + Pembrolizumab + Trigriluzole
Copanlisib + Nivolumab
Ipilimumab + Nivolumab + Paclitaxel
Nivolumab + Ipilimumab
BMS-986277 + Nivolumab
PROSTVAC-V/TRICOM + Nivolumab
BMS-813160 + Nivolumab
GM-CSF + Nivolumab + pTVG-HP plasmid DNA vaccine pTVG-HP plasmid DNA vaccine contains human prostatic acid phosphatase (PAP)-encoding plasmid DNA, which induces cytotoxic immune response towards tumor cells expressing PAP (PMID: 17102977).
Nivolumab + Lenalidomide + Dexamethasone
Rovalpituzumab Tesirine + Nivolumab + Ipilimumab
Nivolumab + rHuPH20
Lenalidomide + Nivolumab
PROSTVAC-V/F + Nivolumab + Ipilimumab
Nab-Rapamycin + Nivolumab
INCAGN01876 + Nivolumab + Ipilimumab
INC280 + Nivolumab
ABBV-368 + Nivolumab
Degarelix + Nivolumab
Ad-RTS-IL-12 plus AL + Nivolumab
Nivolumab + Etoposide + Ifosfamide + Carboplatin
Yttrium-90 + Nivolumab + Ipilimumab
Yttrium-90 + Nivolumab
Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab
Epacadostat + Ipilimumab + Nivolumab
Rovalpituzumab Tesirine + Nivolumab
Ipilimumab + Nivolumab + Vedolizumab
ABBV-927 + Nivolumab
PROSTVAC-V/F + Nivolumab
Cyclophosphamide + IRX-2 + Nivolumab
BMS-986249 + Nivolumab
Cytarabine + Idarubicin + Nivolumab
DEC-205-NY-ESO-1 + Decitabine + Nivolumab + Poly ICLC
Lenalidomide + Nivolumab + Rituximab
BMS-986253 + Degarelix + Nivolumab
Cisplatin + Etoposide + Nivolumab
Epacadostat + Lirilumab + Nivolumab
Mogamulizumab + Nivolumab
Nivolumab + RGX-104
BMS-986012 + Nivolumab
Dacarbazine + Doxorubicin + Vinblastine + Nivolumab
Ipilimumab + Nivolumab + Rituximab
Lirilumab + Nivolumab
Carotuximab + Nivolumab
Nivolumab + NKTR-214 + NKTR-262
Nivolumab + SER-401 Limited information is currently available on SER-401 (Feb, 2019).
CHOP + Nivolumab + Rituximab
Guadecitabine + Nivolumab
Nivolumab + Sunitinib
BMS-986205 + Cisplatin + Gemcitabine + Nivolumab
Carboplatin + Cisplatin + Epacadostat + Gemzar + Nivolumab + Taxol + Pemetrexed
Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab
BMS-986183 + Nivolumab
Bendamustine + Gemcitabine + Nivolumab Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary).
Nivolumab + Vorolanib
Brentuximab vedotin + Nivolumab
DC/myeloma fusion vaccine + Nivolumab
BMS-813160 + Gemcitabine + nab-paclitaxel + Nivolumab
Nivolumab
Axitinib + Nivolumab
INCB081776 + Nivolumab
NKTR-214 + Nivolumab
Nivolumab + Tadalafil
Entinostat + Nivolumab
CRS-207 + Cyclophosphamide + GVAX pancreatic vaccine + Ipilimumab + Nivolumab
Nivolumab + QbG10
Carboplatin + Etoposide + Nivolumab
Carboplatin + Cisplatin + Fluorouracil + Nivolumab
BMS-986148 + Nivolumab
Chidamide + Nivolumab
CB-839 + Nivolumab
Nivolumab + Pegilodecakin
CBM588 + Ipilimumab + Nivolumab CBM588 is a probiotic that induces the release of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which inhibits tumor cell growth (PMID: 23354042).
IRX-2 + Nivolumab Citoplurikin (IRX-2) is an immunotherapeutic comprising a mixture of the cytokines IL-2, IL-1beta, IFN-gamma, TNF-alpha, IL-8, IL-6, and GM-CSF, which may increase anti-tumor immune response (PMID: 19180118, PMID: 23408925).
Nab-paclitaxel + Nivolumab
FT-2102 + Nivolumab FT-2102 specifically targets IDH1 with mutations at amino acid R132, which results in decreased 2HG production and potentially leads to increased differentiation and decreased proliferation of IDH R132-mutant cancer cells (NCI Drug Dictionary).
Nivolumab + Regorafenib
Nivolumab + Valproic acid
Capecitabine + Nivolumab
Ad5CMV-p53 gene + Nivolumab
Nivolumab + Sorafenib
BMS-986310 + Nivolumab
Daratumumab + Nivolumab
Nivolumab + Testosterone cypionate
EPOCH + Nivolumab
BMS-986205 + Nivolumab
GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab GRT-C901 is a personalized priming cancer vaccine that encodes patient tumor-specific neoantigens, potentially resulting in increased anti-tumor immune response against neoantigen-expressing tumor cells (NCI Drug Dictionary).
BMS-986253 + Nivolumab
Veliparib + Nivolumab
Cabiralizumab + Gemcitabine + Nivolumab
Nivolumab + VX15/2503
BMS-986299 + Ipilimumab + Nivolumab
Nivolumab + Pomalidomide Pomalyst (pomalidomide) is a thalidomide derivative that may act to inhibit production of TNF-a, increase T-cell and NK cell activity, increase antibody-dependent cellular toxicity, as well as inhibit angiogenesis and promote cell-cycle arrest in tumors (NCI Drug Dictionary).
Capecitabine + Nivolumab + Oxaliplatin + Relatlimab
DS-8273a + Nivolumab
Azacitidine + Nivolumab
INCB001158 + Nivolumab
CV301 + Nivolumab
Carboplatin + Gemcitabine + Nivolumab
Gemcitabine + nab-paclitaxel + Nivolumab
Fluorouacil + Ipilimumab + Nivolumab
CEP-11981 + Nivolumab
Cisplatin + Nivolumab
Nivolumab + Paclitaxel + Relatlimab
ABBV-428 + Nivolumab
Dasatinib + Nivolumab
Indoximod + Nivolumab
Gemcitabine + Oxaliplatin + Nivolumab
CBP501 + Cisplatin + Nivolumab
Cyclophosphamide + Fludarabine phosphate + Nivolumab
FOLFOX + Nivolumab + Relatlimab
Elotuzumab + Nivolumab
INCB024360 + Nivolumab
Cetuximab + Nivolumab
Nivolumab + Cisplatin + Fluorouacil
Gemcitabine + Nivolumab
CIMAvax-EGF + Nivolumab
Nivolumab + Plinabulin
BMS-986156 + Nivolumab
Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol
Binimetinib + Nivolumab
Carboplatin + Nivolumab + Pemetrexed
Carboplatin + Cisplatin + Gemcitabine + Nivolumab + Paclitaxel + Pemetrexed
Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Nivolumab
Nelfinavir + Nivolumab
Decitabine + Nivolumab + Tetrahydrouridine
JNJ-64041757 + Nivolumab
DSP-7888 + Nivolumab
JTX-2011 + Nivolumab
Ibrutinib + Nivolumab
Nivolumab + Rucaparib
Nivolumab + Relatlimab + TS-1
Nivolumab + Ramucirumab
Nivolumab + Tocilizumab
Talimogene laherparepvec + Nivolumab
Nivolumab + poly ICLC + Rituximab
Ipilimumab + Nivolumab + NeoVax
Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide
Bicalutamide + Ipilimumab + Nivolumab
Nivolumab + Temozolomide
Nivolumab + RP1 Limited information is currently available on RP1 (Feb, 2019).
PT2385 + Nivolumab
Glesatinib + Nivolumab
FANG vaccine + Nivolumab
APX005M + Gemcitabine + nab-paclitaxel + Nivolumab
Carboplatin + Nivolumab
Ipilimumab + Nivolumab + Plinabulin
APX005M + Cabiralizumab + Nivolumab
Docetaxel + Nivolumab
trabectedin + Ipilimumab + Nivolumab
Nivolumab + mFOLFOX-6
BMS-986179 + Nivolumab
Metformin + Nivolumab
Cisplatin + Nivolumab + Pemetrexed
BCG solution + Nivolumab
Nivolumab + Paclitaxel
Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib
Binimetinib + Ipilimumab + Nivolumab
Carfilzomib + Dexamethasone + Nivolumab
INCAGN01949 + Nivolumab
Nivolumab + NeoVax
Enzalutamide + Nivolumab
Capecitabine + Nivolumab + Oxaliplatin
Nivolumab + ONC201 ONC201 (TIC-10) binds to the G-protein coupled receptor, DRD2, leading to inactivation of AKT and ERK, which relocates Foxo3a to the nucleus and then leads to tumor cell apoptosis mediated by (TNF)-related apoptosis-inducing ligand (TRAIL) signaling (PMID: 23390247).
MGCD516 + Nivolumab
Afatinib + Nivolumab
ALT-803 + Nivolumab
Nivolumab + TAK-659
CC-122 + Nivolumab
DCVax-L + Nivolumab
BCG solution + BMS-986205 + Nivolumab
Nivolumab + Ruxolitinib Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (NCI Drug Dictionary). Opdivo (nivolumab) is FDA approved for the treatment of metastatic melanoma, squamous NSCLC, metastatic small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, urothelial carcinoma, Hodgkin's lymphoma, hepatocellular carcinoma, and for dMMR or MSI-H colorectal cancer as a single agent or in combination with Yervoy (ipilimumab) (FDA.gov).
Nivolumab + Carboplatin + Paclitaxel
BMS-986218 + Nivolumab
INCB024360 + Nivolumab + mFOLFOX6
FT500 + Nivolumab
Cyclophosphamide + Nivolumab Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).
CV301 + Nivolumab + mFOLFOX6
BMS-813160 + GVAX pancreatic cancer vaccine + Nivolumab GVAX pancreatic cancer vaccine is composed of irradiated pancreatic ductal adenocarcinoma (PDA) cells engineered to express GM-CSF, which induces T-cell response against PDA cells (PMID: 21217520).
BMS-986207 + Nivolumab
Cisplatin + Gemcitabine + Nivolumab
Cabiralizumab + Nivolumab
GS-5745 + Nivolumab
Carfilzomib + Dexamethasone + Nivolumab + Reolysin
Nivolumab + SYM004
BMS-986205 + Nivolumab + Relatlimab
Nivolumab + TS-1
APX005M + Nivolumab
NEO-PV-01 + Nivolumab + poly ICLC
GEN-009 + Nivolumab
Mocetinostat + Nivolumab
Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine
Niraparib + Nivolumab
Apatinib + Nivolumab
COM701 + Nivolumab
Nivolumab + Relatlimab
Nivolumab + Ipilimumab + Carboplatin + Paclitaxel
INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel
Cabiralizumab + Gemcitabine + Nab-Paclitaxel + Nivolumab
BMS-986242 + Nivolumab
Ipilimumab + Nivolumab + Relatlimab
Nivolumab + REPOCH
INCAGN01949 + Ipilimumab + Nivolumab
Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol
Ad.p53-DC vaccine + Ipilimumab + Nivolumab
DS-8201a + Nivolumab
ACY-241 + Ipilimumab + Nivolumab
FOLFIRINOX + Losartan + Nivolumab
Ceritinib + Nivolumab
Nivolumab + poly ICLC
Blinatumomab + Ipilimumab + Nivolumab
HF10 + Nivolumab
MLN2480 + Nivolumab
Aldesleukin + Nivolumab
Nivolumab + TRK-950
Cabozantinib + Nivolumab
Entinostat + Nivolumab + Ipilimumab
Cabiralizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab
Docetaxel + Nivolumab + Pertuzumab + Trastuzumab
Nivolumab + Pembrolizumab
Nivolumab + Tadalafil + Vancomycin
FOLFIRINOX + Nivolumab
Ipilimumab + Nivolumab + Trametinib